Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. - Wikidata - wikimedia - TriplyDB

Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein.

Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein.

http://www.wikidata.org/entity/Q33594388

about

Phosphatases of α-synuclein, LRRK2, and tau: important players in the phosphorylation-dependent pathology of Parkinsonism Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2.GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1 Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice Leucine-rich repeat kinase 2 regulates autophagy through a calcium-dependent pathway involving NAADP LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress Leucine-rich repeat kinase 2 regulates Sec16A at ER exit sites to allow ER-Golgi export LRRK2 interactions with α-synuclein in Parkinson's disease brains and in cell models LRRK2 expression in idiopathic and G2019S positive Parkinson's disease subjects: a morphological and quantitative study Functional interaction of Parkinson's disease-associated LRRK2 with members of the dynamin GTPase superfamily Membrane localization of LRRK2 is associated with increased formation of the highly active LRRK2 dimer and changes in its phosphorylation Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies LRRK2 regulates synaptogenesis and dopamine receptor activation through modulation of PKA activity Dysregulated LRRK2 signaling in response to endoplasmic reticulum stress leads to dopaminergic neuron degeneration in C. elegans The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel disease Disrupted autophagy leads to dopaminergic axon and dendrite degeneration and promotes presynaptic accumulation of α-synuclein and LRRK2 in the brain Autophagy, mitochondria and oxidative stress: cross-talk and redox signalling Activation Mechanism of LRRK2 and Its Cellular Functions in Parkinson's Disease The Role of Autophagy, Mitophagy and Lysosomal Functions in Modulating Bioenergetics and Survival in the Context of Redox and Proteotoxic Damage: Implications for Neurodegenerative Diseases Mouse Genetic Models of Human Brain Disorders Alpha-synuclein Toxicity in the Early Secretory Pathway: How It Drives Neurodegeneration in Parkinsons Disease Deconvoluting the complexity of autophagy and Parkinson's disease for potential therapeutic purpose The role of ALFY in selective autophagy Mouse models of Parkinson's disease associated with mitochondrial dysfunction Genetically engineered mouse models of Parkinson's disease The involvement of microRNAs in neurodegenerative diseases LRRK2 as a Potential Genetic Modifier of Synucleinopathies: Interlacing the Two Major Genetic Factors of Parkinson's Disease Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications Inflammation and α-synuclein's prion-like behavior in Parkinson's disease--is there a link?The role of the LRRK2 gene in Parkinsonism Upstream deregulation of calcium signaling in Parkinson's disease High LRRK2 levels fail to induce or exacerbate neuronal alpha-synucleinopathy in mouse brain Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice No dopamine cell loss or changes in cytoskeleton function in transgenic mice expressing physiological levels of wild type or G2019S mutant LRRK2 and in human fibroblasts Parkinson's disease: animal models and dopaminergic cell vulnerability Role of α- and β-Synucleins in the Axonal Pathology of Parkinson's Disease and Related Synucleinopathies Gene-environment interactions: key to unraveling the mystery of Parkinson's disease Identification and characterization of a leucine-rich repeat kinase 2 (LRRK2) consensus phosphorylation motif The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling

P2860

Q21131229-C70EE5AD-B3DE-40BF-93F9-8CDE2827F48D Q21135493-65B46153-00FB-477C-9D39-A8B2B1475F8F Q21144926-A54503A2-B86C-4056-813A-2C435CEADBC0 Q24293070-576839A1-1437-4B66-9325-8A665716FD85 Q24293723-86EE3DEC-423D-49E2-91EE-51D21C5F3882 Q24294466-110E5F7A-C15C-4340-85A0-247E4424D239 Q24303851-2B3D7855-7925-44E5-8E4B-AB1950AD9B8E Q24304959-172FB199-E91E-46E1-87BD-B1BE2647F20A Q24307455-64E7AADC-56C4-4446-9006-9C62F11D37E7 Q24310218-D481471A-6892-4E23-AFD1-92911239BE97 Q24316270-B5E8D9FC-91DF-472F-8308-AB6681315152 Q24318474-89E5E0B7-4684-48D4-8207-98D1E2CECEB9 Q24323196-FE8FF741-E39E-4917-96CD-FBC002D4D263 Q24324231-B1AEBC3A-E0D6-428F-96A0-7AC78C76908A Q24339515-637AD296-0641-4D63-970E-1E4E432A23DE Q24599233-6F42BD2B-D688-42BB-9294-890D8B545756 Q24608960-17C1FB21-46BE-4AD2-A28A-163B090D9C1A Q26746897-45D3B8CC-553C-4AE6-9CA0-98B7E2100993 Q26750137-67FF7BAC-CF29-48A6-8AA6-811B03773CED Q26752246-A6ACDEDD-B3CF-4B9A-A771-69D2E3C5AF70 Q26776209-2DF5A4AD-D6C5-4E1C-B52C-0511AA083B4B Q26785491-BEC57FC8-807E-4403-B1D9-E698FBF6330B Q26828736-24975A80-1B7B-4ECC-AC06-DE7665952BE5 Q26829851-C5EDEFAA-26F2-4C93-817C-A9E0568F9770 Q26852964-FFE5AB21-C6FD-4012-B03D-75DFB59F1F3D Q26858788-73D1A1B7-A9F4-4CB6-B0A2-02930FB00332 Q26861279-18CBB339-6022-4040-9828-644FE0F436D2 Q27007413-7A18EBCB-825A-415B-A6BA-C80D5AAF6EE2 Q27013695-DC33B741-F31C-4E7E-9D1A-864158020284 Q27022728-77EC73F4-C80F-4F95-855F-1C58B11189A1 Q27023749-245CDBE7-64FC-4EA9-8E2D-5809E9E5CDFA Q27026384-191DAF0B-2B87-4146-8CB3-455E29E4BFE7 Q27303568-F58E6E5A-FFA6-476B-8D44-AA8EF2CD95AD Q27308060-21FAFB93-EEA6-4263-B172-7027CAD9BAB6 Q27312569-4E8A33D0-D687-4A3E-9C45-A08FFCA35CF6 Q28080503-83A3B10F-A93F-412E-B236-64972DD9FDED Q28083418-B0AF5892-6961-44CA-9CD1-03D2C20B6ADA Q28388674-5698511D-D54C-4EB7-9EEB-78FF3D4DAC5E Q28475942-4F12A54F-C501-4206-889B-FDB246EC0EB7 Q28480459-0A402F5B-4DDA-41CA-8730-BA295F5B5B36

P2860

Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein.

http://www.wikidata.org/entity/Q33594388

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Leucine-rich repeat kinase 2 r ...... elated mutant alpha-synuclein.

@ast

Leucine-rich repeat kinase 2 r ...... elated mutant alpha-synuclein.

@en

type

label

Leucine-rich repeat kinase 2 r ...... elated mutant alpha-synuclein.

@ast

Leucine-rich repeat kinase 2 r ...... elated mutant alpha-synuclein.

@en

prefLabel

Leucine-rich repeat kinase 2 r ...... elated mutant alpha-synuclein.

@ast

Leucine-rich repeat kinase 2 r ...... elated mutant alpha-synuclein.

@en

P1433

Q33594388-7442A092-B954-41E9-BE63-35971ABA0B33

P1476

Q33594388-36C9A217-B1AF-454A-A8DD-3730A6FB30F6

P2093

Q33594388-025AAA66-46D3-4D11-AD9E-1B3A8CAB061D

Q33594388-15925E6A-7A80-41B1-83AC-0078B24E075C

Q33594388-26ECA15E-5955-4C97-81A4-D659195DA515

Q33594388-278D8EB5-6CFE-432A-AC8A-BCCBA70ACC74

Q33594388-59D81952-7B92-4B7D-B933-3AAC1040B241

Q33594388-6895EAD4-A885-4F87-A5DC-1D07E9FE5D97

Q33594388-7DCEE20A-868B-4A9D-9E44-496607FCA573

Q33594388-82A0D369-D6FD-4D37-9AC6-006DE8FE9244

Q33594388-8AE788BA-7ACB-49AB-BE66-082EBDD790BA

Q33594388-8E1F3FAF-9CC7-40CB-9883-423E4BA18A94

P2860

Q33594388-0357E6C1-022A-4223-ADDD-A78607A7C9FC

Q33594388-1AA5DC06-FEDD-424C-9BFA-A0720F65D8D8

Q33594388-1CC10112-16CD-4C3F-B633-214E5703D262

Q33594388-271F70AC-2FE7-4AD9-92F0-5AA9E1BC0218

Q33594388-2AAA3AF1-0D1D-485B-AF35-048578AE418C

Q33594388-306D1B33-36BE-4E3C-8847-544BF5FF6FDF

Q33594388-3195DAAC-B575-4969-9B48-37141F2F6D47

Q33594388-32DBC59E-2C6F-4277-BC00-FBE8CE644559

Q33594388-3C84B941-BC37-48CF-9FE2-0CB1FBEFCAA5

Q33594388-4433FD95-874F-46F8-8342-6516ECD57883

P304

Q33594388-34BCE179-47FF-4D9A-8F90-1571BDCD7D5D

P31

Q33594388-BDCC3D1B-4B47-4F86-A55C-E04E7396BF64

P356

Q33594388-22524105-271B-4FFB-95F4-16431FE5381C

P407

Q33594388-F178CB44-7E66-47C7-88D7-2468DBE3C8DC

P433

Q33594388-C5B42E17-19D0-437A-90D8-DC2DE9D696BF

P478

Q33594388-C650E77B-7C58-4655-9161-AF5EAEED37A9

P50

Q33594388-6451FBAF-974D-4DA0-971D-2C81614E887A

Q33594388-976FF9B8-6916-435E-89FC-AA2A046D786B

Q33594388-9DC53AF7-16B2-43BD-9067-6A4F44ADC002

P577

Q33594388-851717DC-EC18-4700-B595-6D203DF64921

P5875

Q33594388-F0FBF4C0-D46E-4C0F-AAD2-6F44853338C5

P698

Q33594388-4EFED5B2-7914-4DA4-B227-2F635B266B67

P921

Q33594388-6BD30C54-80ED-4693-B6B2-7B052012E610

Q33594388-85012164-AFCB-4906-BAAB-4E56D67BEFD4

P932

Q33594388-F2C8CBE0-27F8-4FD0-B560-AA6A3C046F85

P356

J.NEURON.2009.11.006

P1433

P1476

Leucine-rich repeat kinase 2 r ...... related mutant alpha-synuclein

@en

P2093

Cai-Xia Long

http://www.w3.org/2001/XMLSchema#string

Chengsong Xie

http://www.w3.org/2001/XMLSchema#string

Gay Rudow

http://www.w3.org/2001/XMLSchema#string

Hoon Shim

http://www.w3.org/2001/XMLSchema#string

Jinhui Ding

http://www.w3.org/2001/XMLSchema#string

Juan C Troncoso

http://www.w3.org/2001/XMLSchema#string

Jung-Hwa Tao-Cheng

http://www.w3.org/2001/XMLSchema#string

Lixin Sun

http://www.w3.org/2001/XMLSchema#string

Lizhen Wang

http://www.w3.org/2001/XMLSchema#string

Loukia Parisiadou

http://www.w3.org/2001/XMLSchema#string

P2860

Persistent amyloidosis following suppression of Abeta production in a transgenic model of Alzheimer disease

A protein factor essential for microtubule assembly

Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity

Kinase activity of mutant LRRK2 mediates neuronal toxicity

Localization of LRRK2 to membranous and vesicular structures in mammalian brain

Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models

Alpha-synuclein in Lewy bodies

Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology

Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease

A common LRRK2 mutation in idiopathic Parkinson's disease

P304

807-827

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.NEURON.2009.11.006

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

64

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40906987

http://www.w3.org/2001/XMLSchema#string

P698

20064389

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

2807409

http://www.w3.org/2001/XMLSchema#string